Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. OBJECTIVE: To evaluate the treatment effect of alemtuzumab on low-contrast vision in relapsing–remitting multiple sclerosis (RRMS) patients. METHODS: This was a pre-defined exploratory analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Graves, Jennifer, Galetta, Steven L, Palmer, Jeffrey, Margolin, David H, Rizzo, Marco, Bilbruck, John, Balcer, Laura J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2013
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807733/
https://www.ncbi.nlm.nih.gov/pubmed/23459567
http://dx.doi.org/10.1177/1352458513475722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807733/
https://www.ncbi.nlm.nih.gov/pubmed/23459567
http://dx.doi.org/10.1177/1352458513475722

Ejemplares similares